Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Ernexa Therapeutics (Nasdaq: ERNA) announced the expansion of its Scientific Advisory Board into a combined Scientific and Medical Advisory Board as it prepares for clinical trials in ovarian cancer and autoimmune disease. The company has appointed two distinguished physicians: Dr. Amir Jazaeri from MD Anderson Cancer Center, who will guide the ovarian cancer program, and Dr. Anna Jonsson from the University of Colorado, who will lead translational strategy for the autoimmune pipeline.
This strategic expansion follows Ernexa's recently strengthened financial position and marks its transition from research to clinical-stage development. The enhanced advisory board will support the company's scientific and clinical strategy as it advances its first oncology and autoimmune programs toward IND-enabling studies.
Ernexa Therapeutics (Nasdaq: ERNA) ha annunciato l'ampliamento del suo Comitato Scientifico, che diventa un Comitato Scientifico e Medico congiunto, in preparazione alle sperimentazioni cliniche sul cancro ovarico e sulle malattie autoimmuni. L'azienda ha nominato due medici di spicco: Dr. Amir Jazaeri del MD Anderson Cancer Center, che guider脿 il programma sul cancro ovarico, e Dr. Anna Jonsson dell'Universit脿 del Colorado, che sar脿 responsabile della strategia traslazionale per la pipeline delle malattie autoimmuni.
Questa espansione strategica segue il recente rafforzamento della posizione finanziaria di Ernexa e segna la sua transizione dalla ricerca allo sviluppo in fase clinica. Il comitato ampliato supporter脿 la strategia scientifica e clinica dell'azienda mentre procede con i suoi primi programmi oncologici e autoimmuni verso studi abilitanti IND.
Ernexa Therapeutics (Nasdaq: ERNA) anunci贸 la ampliaci贸n de su Junta Asesora Cient铆fica, que ahora se convierte en una Junta Asesora Cient铆fica y M茅dica combinada, prepar谩ndose para ensayos cl铆nicos en c谩ncer de ovario y enfermedades autoinmunes. La compa帽铆a nombr贸 a dos destacados m茅dicos: Dr. Amir Jazaeri del MD Anderson Cancer Center, quien dirigir谩 el programa de c谩ncer de ovario, y Dr. Anna Jonsson de la Universidad de Colorado, quien liderar谩 la estrategia traslacional para la l铆nea de enfermedades autoinmunes.
Esta expansi贸n estrat茅gica sigue al fortalecimiento reciente de la posici贸n financiera de Ernexa y marca su transici贸n de la investigaci贸n al desarrollo cl铆nico. La junta ampliada apoyar谩 la estrategia cient铆fica y cl铆nica de la empresa mientras avanza con sus primeros programas de oncolog铆a y autoinmunidad hacia estudios habilitantes para IND.
Ernexa Therapeutics (雮橃姢雼�: ERNA)電� 雮滌唽鞎� 氚� 鞛愱皜氅挫棴 歆堩櫂 鞛勳儊 鞁滍棙 欷�牍勲ゼ 鞙勴暣 瓿柬暀 鞛愲鞙勳洂須岆ゼ 瓿柬暀 氚� 鞚橅暀 鞛愲鞙勳洂須岆 頇曤寑頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 霊� 氇呾潣 鞝�氇呿暅 鞚橃偓毳� 鞛勲獏頄堨姷雼堧嫟: 雮滌唽鞎� 頂勲攴鸽灗鞚� 鞚措亴 MD Anderson Cancer Center鞚� Dr. Amir Jazaeri鞕� 鞛愱皜氅挫棴 韺岇澊頂勲澕鞚胳潣 氩堨棴 鞝勲灥鞚� 雼措嫻頃� 旖滊霛茧弰 雽�頃欔祼鞚� Dr. Anna Jonsson鞛呺媹雼�.
鞚措矆 鞝勲灥鞝� 頇曥灔鞚� 斓滉芳 Ernexa鞚� 鞛爼鞝� 旮半皹 臧曧檾鞐� 霐半ジ 瓴冹溂搿�, 鞐瓣惮 雼硠鞐愳劀 鞛勳儊 雼硠 臧滊皽搿滌潣 鞝勴櫂鞚� 鞚橂頃╇媹雼�. 頇曤寑霅� 鞛愲鞙勳洂須岆姅 須岇偓臧� 觳� 氩堨Ц 膦呾枒頃� 氚� 鞛愱皜氅挫棴 頂勲攴鸽灗鞚� IND 鞀轨澑 鞐瓣惮 雼硠搿� 歆勳爠鞁滍偆電� 雿� 鞛堨柎 瓿柬暀鞝� 氚� 鞛勳儊鞝� 鞝勲灥鞚� 歆�鞗愴暊 瓴冹瀰雼堧嫟.
Ernexa Therapeutics (Nasdaq : ERNA) a annonc茅 l'茅largissement de son comit茅 consultatif scientifique en un comit茅 consultatif scientifique et m茅dical combin茅, en vue des essais cliniques sur le cancer de l'ovaire et les maladies auto-immunes. La soci茅t茅 a nomm茅 deux m茅decins 茅minents : Dr Amir Jazaeri du MD Anderson Cancer Center, qui supervisera le programme sur le cancer de l'ovaire, et Dr Anna Jonsson de l'Universit茅 du Colorado, qui dirigera la strat茅gie translationnelle pour la pipeline des maladies auto-immunes.
Cette expansion strat茅gique fait suite au renforcement r茅cent de la situation financi猫re d'Ernexa et marque sa transition de la recherche au d茅veloppement clinique. Le comit茅 consultatif 茅largi soutiendra la strat茅gie scientifique et clinique de la soci茅t茅 alors qu'elle fait progresser ses premiers programmes en oncologie et auto-immunit茅 vers des 茅tudes permettant l'IND.
Ernexa Therapeutics (Nasdaq: ERNA) gab die Erweiterung seines Wissenschaftlichen Beirats zu einem kombinierten Wissenschaftlichen und Medizinischen Beirat bekannt, um sich auf klinische Studien bei Eierstockkrebs und Autoimmunerkrankungen vorzubereiten. Das Unternehmen hat zwei angesehene 脛rzte berufen: Dr. Amir Jazaeri vom MD Anderson Cancer Center, der das Eierstockkrebsprogramm leiten wird, und Dr. Anna Jonsson von der University of Colorado, die die translationale Strategie f眉r die Autoimmun-Pipeline verantwortet.
Diese strategische Erweiterung folgt auf die k眉rzlich gest盲rkte Finanzlage von Ernexa und markiert den 脺bergang von der Forschung zur klinischen Entwicklung. Der erweiterte Beirat wird die wissenschaftliche und klinische Strategie des Unternehmens unterst眉tzen, w盲hrend es seine ersten onkologischen und autoimmunen Programme auf IND-f盲hige Studien voranbringt.
- Strategic expansion of advisory board with two renowned medical experts
- Recently strengthened financial position
- Progression toward clinical trials in both oncology and autoimmune programs
- Addition of expertise in gynecologic oncology and autoimmune diseases
- None.
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa鈥檚 Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa鈥檚 transition from research to clinical-stage development. This comes on the heels of Ernexa鈥檚 recently strengthened financial position and is part of a broader strategy to accelerate its lead programs toward the clinic.
Joining the advisory board are two distinguished physicians: Amir Anthony Jazaeri, M.D., a leader in gynecologic oncology at , and Anna Helena Jonsson, M.D., Ph.D., an expert in autoimmune disease and immunology at the . Dr. Jazaeri will help guide the company鈥檚 ovarian cancer program into the clinic, while Dr. Jonsson will lead translational strategy for Ernexa鈥檚 autoimmune pipeline.
鈥淎s we prepare to advance our programs into clinical development, we鈥檙e proud to welcome renowned medical leaders to guide us,鈥� said Sanjeev Luther, President and CEO of Ernexa Therapeutics. 鈥淎s we move toward key inflection points in our pipeline, their deep expertise in translational medicine and patient-centered innovation will be instrumental in advancing our lead programs. Our team is laser-focused on delivering transformative treatments for patients living with ovarian cancer and autoimmune diseases.鈥�
The board will support Ernexa鈥檚 scientific and clinical strategy as the company advances its first oncology and autoimmune programs toward IND-enabling studies. Their expertise will inform trial design, biomarker development, and regulatory engagement.
Dr. Jazaeri is a professor of gynecological oncology at MD Anderson and is the department鈥檚 Vice Chair for Clinical Research. He is also Director of the Gynecologic Cancer Immunotherapy Program. With extensive experience in adoptive cell therapies, vaccines, and immune checkpoint inhibitors, Dr. Jazaeri has built one of the field鈥檚 most robust clinical immunotherapy programs focused on gynecologic cancers. His research also spans novel intraperitoneal therapies and tumor microenvironment profiling.
Dr. Jonsson is a physician-scientist and rheumatologist whose research at the University of Colorado Anschutz Medical Campus explores the understudied role of CD8 T cells in autoimmune diseases, particularly rheumatoid arthritis and systemic lupus erythematosus (SLE). Her work, which has included prominent roles in the NIH鈥檚 Accelerating Medicines Partnership (AMP): RA/SLE Network, leverages single-cell technologies to identify immune drivers of chronic inflammation. She also maintains an active clinical practice, ensuring that her scientific insights are closely tied to patient needs.
The company鈥檚 new advisory board structure is designed to integrate scientific discovery with clinical strategy as Ernexa advances novel cell therapies for diseases with high unmet medical needs.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa鈥檚 core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa鈥檚 allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting.
ERNA-101 is the company鈥檚 lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company鈥檚 initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit .
Dr. Jazaeri and Dr. Jonsson receive compensation as members of the Ernexa Therapeutics medical advisory board, and this financial relationship has been disclosed to the respective organizations鈥� Conflict of Interest Committees in accordance with institutional policies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company鈥檚 lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC, including its recent filings on Form 8-K, Form 10-K, and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
Who are the new members of Ernexa Therapeutics' (ERNA) Scientific and Medical Advisory Board?
What therapeutic areas is Ernexa Therapeutics (ERNA) focusing on for clinical development?
What is the significance of Ernexa's (ERNA) advisory board expansion in June 2025?
What will be the role of the new Scientific and Medical Advisory Board at Ernexa (ERNA)?
